Meldonium

Meldonium, known widely by the brand name Mildronate and chemically as 3-(2,2,2-trimethylhydrazinium)propionate dihydrate, is a small-molecule metabolic modulator developed at the Latvian Institute of Organic Synthesis during the late Soviet era by a team associated with the chemist Ivars Kalvinsh ^[1][3]. Structurally it is a close analog of gamma-butyrobetaine, the natural precursor from which the body manufactures carnitine, and that mimicry sits at the center of how the compound behaves ^[2].

Pharmacologically, meldonium is classified as an anti-ischemic and cardioprotective drug. Its principal targets are gamma-butyrobetaine hydroxylase, the enzyme that catalyzes the final step of carnitine synthesis, and the carnitine transporter OCTN2, which governs carnitine uptake into tissues ^[2]. By restraining both, the compound lowers tissue carnitine and shifts cellular fuel use away from fatty acid oxidation toward glucose oxidation, a route that yields more energy per unit of oxygen and is therefore favored when blood flow is limited ^[1][2].

Clinically, meldonium has been used for decades across the Baltic states and other post-Soviet countries for stable angina, chronic heart failure, recovery after myocardial infarction, and disorders of cerebral circulation, where reports describe improved mood and activity alongside reduced dizziness and fatigue ^[3]. Reviews note that despite this long record of use, rigorous large-scale clinical trials remain relatively scarce ^[6].

Regulatory status is a defining feature of its story. Meldonium holds marketing authorization in several ex-Soviet republics but not in the European Union or the United States ^[5]. The World Anti-Doping Agency placed it on its monitoring program in 2015 and added it to the prohibited list of metabolic modulators on 1 January 2016, after which it became widely known through high-profile athletic cases ^[6][5]. It is typically supplied as capsules, tablets, oral syrup, and injectable solution ^[3].

Meldonium is generally well tolerated, with occasional GI upset, headache, or agitation. It is not FDA-approved and has been banned in sport by WADA since 2016. Use should follow appropriate medical guidance.

Meldonium was synthesized in the mid-1970s at the Institute of Organic Synthesis in Riga, Latvia, by a team associated with the chemist Ivars Kalvins, and it was marketed as Mildronate. Developed with cardiovascular applications in mind, it became a widely prescribed anti-ischemic and cardioprotective drug across the former Soviet Union and Eastern Europe. Its mechanism as an inhibitor of carnitine biosynthesis, and the resulting metabolic shift toward more oxygen-efficient glucose oxidation, was characterized largely by Latvian researchers over subsequent decades. The compound gained global attention in 2016, when the World Anti-Doping Agency added it to its list of prohibited substances following evidence of widespread use among elite athletes. It has never been approved by the United States Food and Drug Administration.

Meldonium enjoys a solid clinical reputation in the countries where it is registered, valued as an oxygen-thrifty cardioprotective and anti-ischemic agent with an unusually well-defined metabolic mechanism. Sports scientists and clinicians alike find its carnitine-lowering, glucose-favoring action genuinely interesting, and it is among the most discussed metabolic modulators of the past decade. Its role in cardiovascular and rehabilitation settings has been reviewed extensively, though authors consistently note that rigorous performance-enhancement data in healthy athletes remain limited. The 2016 doping controversy raised its profile considerably while also underscoring that its benefits in sport are more assumed than proven. It remains unapproved in Western markets, so most discussion draws on Eastern European clinical literature.